Android app Apple app link

Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials

By Yahoo! Finance   |   1 month ago
Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials

Arcus Biosciences Inc. (NYSE:RCUS) recently announced positive data for its kidney cancer drug casdatifan, showing promising results in Phase 1/1b studies.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.